TNF and autoimmune disease: TNF-α inhibitors represent cornerstone therapeutics for pediatric refractory autoimmune diseases, yet demand stringent adherence to approved indications, proactive surveillance of infection and malignancy risks, and personalized treatment regimens.Current guidelines recommend initiating biologic therapy after failure of conventional treatments such as methotrexate or glucocorticoids [9].